TP53 and B-cell chronic lymphocytic leukemia: Ibrutinib, as the first BTKi, has profoundly altered the treatment paradigm of CLL patients, particularly relapsed/refractory CLL (R/R CLL) and high-risk patients with TP53 aberrations (12–14).